Cargando…

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem

Detalles Bibliográficos
Autores principales:	Vallianou, Natalia G., Christodoulatos, Gerasimos Socrates, Kounatidis, Dimitris, Dalamaga, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989208/ https://www.ncbi.nlm.nih.gov/pubmed/33782668 http://dx.doi.org/10.1016/j.metop.2021.100089

Ejemplares similares

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
por: Cefalo, Chiara Maria Assunta, et al.
Publicado: (2019)

Mycobiome and Cancer: What Is the Evidence?
por: Vallianou, Natalia, et al.
Publicado: (2021)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015)

Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives
por: Vallianou, Natalia, et al.
Publicado: (2021)

The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives
por: Vallianou, Natalia G., et al.
Publicado: (2023)

SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century?
por: Kounatidis, Dimitris, et al.
Publicado: (2023)

Understanding the Co-Epidemic of Obesity and COVID-19: Current Evidence, Comparison with Previous Epidemics, Mechanisms, and Preventive and Therapeutic Perspectives
por: Dalamaga, Maria, et al.
Publicado: (2021)

Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials
por: Musso, Giovanni, et al.
Publicado: (2019)

Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload
por: Young, Sophia L., et al.
Publicado: (2021)

Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges
por: Tsilingiris, Dimitrios, et al.
Publicado: (2023)

Diagnostic and Prognostic Value of Serum Omentin-1 in Sepsis: A Prospective Study in Critically Ill Patients
por: Karampela, Irene, et al.
Publicado: (2023)

The anti-inflammatory effects of SGLT inhibitors
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

Diverting epithelial-to-mesenchymal transition to transform cancer cells to adipocytes: A promising strategy to stop metastasis
por: Dalamaga, Maria, et al.
Publicado: (2019)

SGLT2 Inhibitors: the Gift that Keeps on Giving
por: Garcia, Maria Victoria Faith, et al.
Publicado: (2021)

Renal Effects of SGLT2 Inhibitors and Potential Clinical Implications: Beyond the Heart
por: Lee, Sunki
Publicado: (2022)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
por: Spatola, Leonardo, et al.
Publicado: (2017)

Circulating Chemerin and Its Kinetics May Be a Useful Diagnostic and Prognostic Biomarker in Critically Ill Patients with Sepsis: A Prospective Study
por: Karampela, Irene, et al.
Publicado: (2022)

Editorial to the IJMS Special Issue on Sglt2 Inhibitors Vol. 1
por: Lymperopoulos, Anastasios
Publicado: (2023)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

Circulating Omentin-1 as a Biomarker at the Intersection of Postmenopausal Breast Cancer Occurrence and Cardiometabolic Risk: An Observational Cross-Sectional Study
por: Christodoulatos, Gerasimos Socrates, et al.
Publicado: (2021)

SGLT2 Inhibitors: Statins or ACE-Inhibitors of the 21st Century?
por: Correale, Michele, et al.
Publicado: (2023)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Evolving insights into the pleiotropic cardioprotective mechanisms of SGLT2 inhibitors
por: Fender, Anke C., et al.
Publicado: (2023)

Structural mechanism of SGLT1 inhibitors
por: Niu, Yange, et al.
Publicado: (2022)

SGLT2 INHIBITORS - SOMETHING IN THE WATER, OR THE HEART OF THE MATTER?
por: Esmonde, S, et al.
Publicado: (2020)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

Could hyperglycemia-induced cardiac autoimmunity be hidden behind cardiovascular disease in type 1 diabetes mellitus?
por: Vallianou, Natalia, et al.
Publicado: (2019)

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
por: Kanduri, Swetha R., et al.
Publicado: (2020)

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
por: Nomiyama, Takashi
Publicado: (2020)

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
por: Butler, Javed, et al.
Publicado: (2020)

Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
por: Theofilis, Panagiotis, et al.
Publicado: (2023)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
por: Zhang, Yu, et al.
Publicado: (2023)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
por: Pitt, Bertram, et al.
Publicado: (2022)

Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice
por: David-Silva, Aline, et al.
Publicado: (2020)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
por: Lee, Mei-Chuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8qei01bkdpqs4udl5pm4gtiio4